Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 3, 2011, Pages 295-299

  Kato, Yuya ^a   Ichida, Fukiko ^a   Saito, Kazuyoshi ^a   Watanabe, Kazuhiro ^a   Hirono, Keiichi ^a   Miyawaki, Toshio ^a   Yoshimura, Naoki ^a   Horiuchi, Isao ^a   Taguchi, Masato ^a   Hashimoto, Yukiya ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Japanese pediatric patients; VKORC1; Warfarin

Indexed keywords

CYSTEINE; CYTOCHROME P450 2C9; THREONINE; WARFARIN;

ADOLESCENT; ADULT; ANTICOAGULATION; CHILD; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENOTYPE; HUMAN; INFANT; INTERNATIONAL NORMALIZED RATIO; JAPANESE; MALE; NOTE; PHARMACOGENETICS; PRESCHOOL CHILD; PROTHROMBIN TIME; REGULATOR GENE; SCHOOL CHILD; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1 GENE;

EID: 79959950122     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-NT-082     Document Type: Note

References (13)

1. Michelson, A. D., Bovill, E., Monagle, P. and Andrew, M.: Antithrombotic therapy in children. Chest, 114: 748s-769s (1998).
2. Kosaki, K., Yamaghishi, C., Sato, R., Semejima, H., Fuijita, H., Tamura, K., Maeyama, K., Yamagishi, H., Sugaya, A., Dodo, H., Tanigawara, Y. and Takahashi, T.: 1173ChT polymorphism in VKORC1 modulates the required warfarin dose. Pediatr. Cardiol., 27: 685-688 (2006).
3. Obayashi, K., Nakamura, K., Kawana, J., Ogata, H., Hanada, K., Kurabayashi, M., Hasegawa, A., Yamamoto, K. and Horiuchi, R.: VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin. Pharmacol. Ther., 80: 169-178 (2006).
4. Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J. and Trager, W. F.: Hydroxylation of warfarin by human cDNAexpressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol., 5: 54-59 (1992).
5. Nasu, K., Kubota, T. and Ishizaki, T.: Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics, 7: 405-409 (1997).
6. DöAndrea, G., DöAmbrosio, R. L., Di Perna, P., Chetta, M., Santacroce, R., Brancaccio, V., Grandone, E. and Margaglione, M.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood, 105: 645-649 (2005).
7. Takahashi, H., Wilkinson, G. R., Nutescu, E. A., Morita, T., Ritchie, M. D., Scordo, M. G., Pengo, V., Barban, M., Padrini, R., Ieiri, I., Otsubo, K., Kashima, T., Kimura, S., Kijima, S. and Echizen, H.: Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics, 16: 101-110 (2006).
8. Taguchi, M., Hongou, K., Yagi, S., Miyawaki, T., Takizawa, M., Aiba, T. and Hashimoto, Y.: Evaluation of phenytoin dosage regimens based on genotyping of CYP2C subfamily in routinely treated Japanese patients. Drug Metab. Pharmacokinet., 20: 107-112 (2005).
9. Beal, S. L., Boeckmann, A. J. and Sheiner, L. B.: NONMEM Users Guides: NONMEM Project Group, University of California, San Francisco (1992).
10. Zhang, J. E., Jorgensen, A. L., Alfirevic, A., Williamson, P. R., Toh, C. H., Park, B. K. and Pirmohamed, M.: Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. Pharmacogenet. Genomics, 19: 781-789 (2009).
11. Caldwell, M. D., Awad, T., Johnson, J. A., Gage, B. F., Falkowski, M., Gardina, P., Hubbard, J., Turpaz, Y., Langaee, T. Y., Eby, C., King, C. R., Brower, A., Schmelzer, J. R., Glurich, I., Vidaillet, H. J., Yale, S. H., Qi Zhang, K., Berg, R. L. and Burmester, J. K.: CYP4F2 genetic variant alters required warfarin dose. Blood, 111: 4106-4112 (2008).
12. Cha, P. C., Mushiroda, T., Takahashi, A., Kubo, M., Minami, S., Kamatani, N. and Nakamura, Y.: Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum. Mol. Genet., 19: 4735-4744 (2010).
13. Takahashi, H., Ishikawa, S., Nomoto, S., Nishigaki, Y., Ando, F., Kashima, T., Kimura, S., Kanamori, M. and Echizen, H.: Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin. Pharmacol. Ther., 68: 541-555 (2000).